+ Watch DSCI
on My Watchlist
A nice uptick in quarterly revenues wasn't enough to keep Derma from sliding into the end of 2013 on a downward note. Their main issue has been difficulty enrolling their phase III trials of DSC127 for diabetic foot ulcers, which is somewhat mystifying considering they have 80 clinical sites, are only attempting to enroll 100 patients, and are studying one of the more common medical problems in existence. They've even hired a firm that specializes in improving trial enrollment, a move I've never seen a biopharma company admit to until now. What exactly the problem is, I can't imagine. I just know it's going to be a long time until we see topline data from the pivotal trials (I'm guessing 2016) and Derma is continuing to lose money. With 27M in cash and a quarterly burn of about 5M, I think a dilutive financing is in the cards. A sharp upturn in the current winter biopharma frenzy seems like an opportune moment to register my pessimism.
IBD EPS, RS, SPROE, Acc ratings plus P/E and div yieldMEDICAL 1 92 EA NEG EARNINGS
just looking to track and look into more
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions